A new player in hemolytic uremic syndrome: the plasma kallikrein-kinin system, a target of heme

This commentary by Francois Alhenc-Gelas discusses the findings of Gerogianni et al., which investigate the role of the plasma kallikrein-kinin system in hemolytic uremic syndrome (HUS) and its activation by heme. The authors aim to understand the pathophysiological implications of this activation and its potential clinical consequences in HUS. The study highlights the importance of heme in the activation of coagulation factors and the subsequent release of bioactive peptides, suggesting a new avenue for understanding and treating HUS.